On 10 January 2019
The Board of Caplin Point Laboratories will meet on 10 January 2018 to consider and approve the Business Transfer Agreement to be entered into with its Wholly Owned Subsidiary Company, Caplin Steriles, for transfer of business undertaking of the Company (Regulated Markets Injectable Business, including US FDA approved Injectable Plant and DSIR recognized R&D Units CP4 and CP5), besides considering other allied subjects pursuant to the approval granted by the members of the Company through Postal Ballot.Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)